PDF(Pubmed)
Abstract：
Managing advanced basal cell carcinoma (BCC) in patients with Gorlin-Goltz syndrome presents unique clinical challenges due to the tumor\'s aggressive nature and potential for widespread metastasis. This case study details a sequential treatment regimen for a 68-year-old female patient with an extensive, inoperable BCC. Employing a multimodal approach that integrates radiotherapy, the Hedgehog pathway inhibitor vismodegib, and High-Intensity Focused Ultrasound (HIFU), we demonstrate the potential for nearly complete remission in a patient with advanced BCC. Initial treatment with radiotherapy and vismodegib reduced tumor size significantly, but the largest mass displayed resistance over time, signifying the need for innovative therapies. Subsequent HIFU treatment targeted individual lesions, showcasing a non-invasive method that provided precise treatment while mitigating systemic side effects. The case emphasizes the necessity of continual adaptation in treatment plans to address the development of resistance and underscores the importance of incorporating new technologies and targeted therapies for complex BCC cases. The successful outcome of this integrated strategy suggests a promising direction for future research and highlights the importance of multidisciplinary approaches that tailor treatment to individual patient needs, tumor characteristics, and evolving therapeutic landscapes.
摘要：
由于肿瘤的侵袭性和广泛转移的潜力，在Gorlin-Goltz综合征患者中管理晚期基底细胞癌（BCC）提出了独特的临床挑战。本案例研究详细介绍了一名68岁女性患者的序贯治疗方案，不可操作的BCC。采用整合放射治疗的多模式方法，Hedgehog通路抑制剂vismodegib，和高强度聚焦超声（HIFU），我们证明了晚期BCC患者几乎完全缓解的可能性.放疗和vismodegib的初始治疗显着减小了肿瘤大小，但是随着时间的推移，最大的质量显示出阻力，这表明需要创新疗法。随后的HIFU治疗针对个别病变，展示了一种非侵入性的方法，提供精确的治疗，同时减轻全身副作用。该案例强调了在治疗计划中持续适应以解决耐药性发展的必要性，并强调了为复杂的BCC病例纳入新技术和靶向治疗的重要性。这一综合战略的成功结果为未来的研究提出了一个有希望的方向，并强调了多学科方法的重要性，这些方法可以根据个人患者的需求进行治疗。肿瘤特征，和不断发展的治疗景观。
